🇺🇸 Tuberculin purified protein derivative in United States

73 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Erythema — 13 reports (17.81%)
  2. Pruritus — 11 reports (15.07%)
  3. Rash — 9 reports (12.33%)
  4. Nausea — 7 reports (9.59%)
  5. Asthenia — 6 reports (8.22%)
  6. Injection Site Erythema — 6 reports (8.22%)
  7. Injection Site Pain — 6 reports (8.22%)
  8. Fall — 5 reports (6.85%)
  9. Headache — 5 reports (6.85%)
  10. Pain — 5 reports (6.85%)

Source database →

Tuberculin purified protein derivative in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Tuberculin purified protein derivative approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Tuberculin purified protein derivative in United States?

Assiut University is the originator. The local marketing authorisation holder may differ — check the official source linked above.